Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response –OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd.
Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), ...
Now, President Trump is poised to fix the marijuana rescheduling issue.From DEA unconstitutional tribunals to Anne Milgram ...
(PRs) among 13 evaluable non-small cell lung cancer (NSCLC) patients (ORR 38%); 1 confirmed PR among 7 breast cancer patientsFavorable safety and PK profile, with encouraging activity, demonstrate a ...
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback